S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
Log in
NASDAQ:IMMP

Immutep Competitors

$2.68
-0.01 (-0.37 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.61
Now: $2.68
$2.76
50-Day Range
$2.68
MA: $3.23
$3.56
52-Week Range
$0.53
Now: $2.68
$7.95
Volume553,179 shs
Average Volume853,189 shs
Market Capitalization$104.52 million
P/E RatioN/A
Dividend YieldN/A
Beta2.23

Competitors

Immutep (NASDAQ:IMMP) Vs. IMNM, KALA, CUE, FULC, EOLS, and ATHX

Should you be buying IMMP stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Immutep, including Immunome (IMNM), Kala Pharmaceuticals (KALA), Cue Biopharma (CUE), Fulcrum Therapeutics (FULC), Evolus (EOLS), and Athersys (ATHX).

Immunome (NASDAQ:IMNM) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Earnings and Valuation

This table compares Immunome and Immutep's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunomeN/AN/A$-10,440,000.00N/AN/A
Immutep$4.92 million21.24$-9,040,000.00N/AN/A

Immutep has higher revenue and earnings than Immunome.

Analyst Ratings

This is a summary of recent ratings for Immunome and Immutep, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunome00203.00
Immutep00203.00

Immunome presently has a consensus price target of $18.00, indicating a potential downside of 54.52%. Immutep has a consensus price target of $7.00, indicating a potential upside of 161.19%. Given Immutep's higher possible upside, analysts clearly believe Immutep is more favorable than Immunome.

Insider & Institutional Ownership

0.2% of Immutep shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Immunome and Immutep's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunomeN/AN/AN/A
ImmutepN/AN/AN/A

Summary

Immutep beats Immunome on 4 of the 4 factors compared between the two stocks.

Kala Pharmaceuticals (NASDAQ:KALA) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Profitability

This table compares Kala Pharmaceuticals and Immutep's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kala Pharmaceuticals-1,794.36%-93.73%-43.09%
ImmutepN/AN/AN/A

Insider & Institutional Ownership

67.6% of Kala Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.2% of Immutep shares are owned by institutional investors. 34.2% of Kala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Kala Pharmaceuticals has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, Immutep has a beta of 2.23, indicating that its share price is 123% more volatile than the S&P 500.

Earnings and Valuation

This table compares Kala Pharmaceuticals and Immutep's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kala Pharmaceuticals$6.07 million68.45$-94,350,000.00($2.76)-2.68
Immutep$4.92 million21.24$-9,040,000.00N/AN/A

Immutep has lower revenue, but higher earnings than Kala Pharmaceuticals.

Analyst Ratings

This is a summary of recent ratings for Kala Pharmaceuticals and Immutep, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kala Pharmaceuticals01602.86
Immutep00203.00

Kala Pharmaceuticals presently has a consensus price target of $20.8571, indicating a potential upside of 181.47%. Immutep has a consensus price target of $7.00, indicating a potential upside of 161.19%. Given Kala Pharmaceuticals' higher possible upside, analysts clearly believe Kala Pharmaceuticals is more favorable than Immutep.

Cue Biopharma (NASDAQ:CUE) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Profitability

This table compares Cue Biopharma and Immutep's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cue Biopharma-1,142.70%-63.69%-50.08%
ImmutepN/AN/AN/A

Insider and Institutional Ownership

64.5% of Cue Biopharma shares are owned by institutional investors. Comparatively, 0.2% of Immutep shares are owned by institutional investors. 9.5% of Cue Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Cue Biopharma has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500. Comparatively, Immutep has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500.

Valuation and Earnings

This table compares Cue Biopharma and Immutep's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cue Biopharma$3.46 million119.10$-36,700,000.00($1.66)-8.20
Immutep$4.92 million21.24$-9,040,000.00N/AN/A

Immutep has higher revenue and earnings than Cue Biopharma.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Cue Biopharma and Immutep, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cue Biopharma00503.00
Immutep00203.00

Cue Biopharma presently has a consensus price target of $31.00, indicating a potential upside of 127.77%. Immutep has a consensus price target of $7.00, indicating a potential upside of 161.19%. Given Immutep's higher possible upside, analysts plainly believe Immutep is more favorable than Cue Biopharma.

Summary

Immutep beats Cue Biopharma on 7 of the 11 factors compared between the two stocks.

Fulcrum Therapeutics (NASDAQ:FULC) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Profitability

This table compares Fulcrum Therapeutics and Immutep's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fulcrum TherapeuticsN/A-71.94%-56.24%
ImmutepN/AN/AN/A

Insider and Institutional Ownership

72.5% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Immutep shares are owned by institutional investors. 30.3% of Fulcrum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Fulcrum Therapeutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Immutep has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500.

Valuation and Earnings

This table compares Fulcrum Therapeutics and Immutep's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fulcrum TherapeuticsN/AN/A$-82,680,000.00($8.13)-1.55
Immutep$4.92 million21.24$-9,040,000.00N/AN/A

Immutep has higher revenue and earnings than Fulcrum Therapeutics.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Fulcrum Therapeutics and Immutep, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fulcrum Therapeutics11502.57
Immutep00203.00

Fulcrum Therapeutics presently has a consensus price target of $18.1667, indicating a potential upside of 44.07%. Immutep has a consensus price target of $7.00, indicating a potential upside of 161.19%. Given Immutep's stronger consensus rating and higher possible upside, analysts plainly believe Immutep is more favorable than Fulcrum Therapeutics.

Summary

Immutep beats Fulcrum Therapeutics on 7 of the 10 factors compared between the two stocks.

Evolus (NASDAQ:EOLS) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Profitability

This table compares Evolus and Immutep's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evolus-120.63%-121.11%-30.91%
ImmutepN/AN/AN/A

Insider and Institutional Ownership

21.7% of Evolus shares are owned by institutional investors. Comparatively, 0.2% of Immutep shares are owned by institutional investors. 10.1% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Evolus has a beta of 2.69, indicating that its stock price is 169% more volatile than the S&P 500. Comparatively, Immutep has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500.

Valuation and Earnings

This table compares Evolus and Immutep's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evolus$34.92 million11.70$-90,030,000.00($3.19)-3.80
Immutep$4.92 million21.24$-9,040,000.00N/AN/A

Immutep has lower revenue, but higher earnings than Evolus.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Evolus and Immutep, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evolus14502.40
Immutep00203.00

Evolus presently has a consensus price target of $13.00, indicating a potential upside of 7.35%. Immutep has a consensus price target of $7.00, indicating a potential upside of 161.19%. Given Immutep's stronger consensus rating and higher possible upside, analysts plainly believe Immutep is more favorable than Evolus.

Summary

Immutep beats Evolus on 7 of the 12 factors compared between the two stocks.

Athersys (NASDAQ:ATHX) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Athersys and Immutep, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Athersys00403.00
Immutep00203.00

Athersys presently has a consensus price target of $9.00, indicating a potential upside of 341.18%. Immutep has a consensus price target of $7.00, indicating a potential upside of 161.19%. Given Athersys' higher possible upside, equities analysts plainly believe Athersys is more favorable than Immutep.

Profitability

This table compares Athersys and Immutep's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AthersysN/A-176.56%-112.67%
ImmutepN/AN/AN/A

Volatility & Risk

Athersys has a beta of -1.54, indicating that its stock price is 254% less volatile than the S&P 500. Comparatively, Immutep has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500.

Insider and Institutional Ownership

27.9% of Athersys shares are owned by institutional investors. Comparatively, 0.2% of Immutep shares are owned by institutional investors. 12.6% of Athersys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Athersys and Immutep's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Athersys$5.63 million71.64$-44,580,000.00($0.29)-7.03
Immutep$4.92 million21.24$-9,040,000.00N/AN/A

Immutep has lower revenue, but higher earnings than Athersys.

Summary

Athersys beats Immutep on 6 of the 10 factors compared between the two stocks.


Immutep Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Immunome logo
IMNM
Immunome
1.1$39.58-3.4%$417.25 millionN/A0.00Upcoming Earnings
Increase in Short Interest
Gap Down
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$7.41-4.5%$415.52 million$6.07 million-3.55Earnings Announcement
Analyst Downgrade
News Coverage
Gap Down
Cue Biopharma logo
CUE
Cue Biopharma
1.3$13.61-2.8%$412.08 million$3.46 million-8.67News Coverage
Fulcrum Therapeutics logo
FULC
Fulcrum Therapeutics
1.5$12.61-1.3%$411.93 millionN/A-4.38Upcoming Earnings
Analyst Downgrade
News Coverage
Gap Down
Evolus logo
EOLS
Evolus
1.1$12.11-5.0%$408.70 million$34.92 million-5.97Upcoming Earnings
Analyst Downgrade
Analyst Revision
Gap Up
Athersys logo
ATHX
Athersys
1.3$2.04-2.0%$403.31 million$5.63 million-5.51News Coverage
Gap Down
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$3.89-0.3%$403.19 million$102.31 million5.81
XOMA logo
XOMA
XOMA
1.8$36.20-0.0%$399.00 million$18.37 million-32.61Decrease in Short Interest
Verastem logo
VSTM
Verastem
1.8$2.35-0.4%$398.97 million$17.46 million-1.67Analyst Upgrade
UroGen Pharma logo
URGN
UroGen Pharma
1.9$19.05-6.3%$398.09 million$20,000.00-2.98Upcoming Earnings
Gap Down
Puma Biotechnology logo
PBYI
Puma Biotechnology
1.6$9.96-5.9%$396.03 million$272.30 million-6.96Earnings Announcement
News Coverage
Gap Down
RedHill Biopharma logo
RDHL
RedHill Biopharma
1.4$9.50-4.6%$395.08 million$6.29 million-5.46Upcoming Earnings
Analyst Upgrade
Gap Down
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
1.4$1.19-2.5%$385.46 millionN/A-0.34Analyst Report
Increase in Short Interest
Gap Down
VYNE Therapeutics logo
VYNE
VYNE Therapeutics
1.8$7.46-5.8%$382.90 million$10.64 million-1.99Upcoming Earnings
Gap Down
Forte Biosciences logo
FBRX
Forte Biosciences
1.6$28.49-1.2%$365.56 million$40,000.00-1.24
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.85-0.1%$362.86 million$57.49 million-6.60Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Nabriva Therapeutics logo
NBRV
Nabriva Therapeutics
1.3$2.39-0.8%$360.38 million$9.48 million-0.41Analyst Upgrade
Increase in Short Interest
Analyst Revision
Gap Down
ANI Pharmaceuticals logo
ANIP
ANI Pharmaceuticals
1.7$29.10-1.7%$359.62 million$206.55 million-14.62Gap Down
Oncorus logo
ONCR
Oncorus
1.6$15.80-4.1%$357.36 millionN/A0.00Upcoming Earnings
Decrease in Short Interest
Gap Down
Aeglea BioTherapeutics logo
AGLE
Aeglea BioTherapeutics
1.7$7.45-0.8%$357.13 million$3.89 million-3.90Upcoming Earnings
News Coverage
Verrica Pharmaceuticals logo
VRCA
Verrica Pharmaceuticals
1.1$13.71-3.6%$354.62 millionN/A-10.39Analyst Downgrade
Gap Down
Sesen Bio logo
SESN
Sesen Bio
1.2$2.72-3.7%$351.81 millionN/A-6.18Decrease in Short Interest
Gap Up
VistaGen Therapeutics logo
VTGN
VistaGen Therapeutics
1.3$2.47-10.5%$349.98 millionN/A-5.15Analyst Report
News Coverage
Gap Up
Fortress Biotech logo
FBIO
Fortress Biotech
1.3$3.72-0.3%$348.58 million$36.63 million-4.38Analyst Report
News Coverage
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$7.48-1.9%$341.40 million$16.54 million-3.04Analyst Downgrade
News Coverage
Trevena logo
TRVN
Trevena
1.4$2.15-1.9%$336.83 million$30,000.00-9.33Analyst Downgrade
Gap Down
CymaBay Therapeutics logo
CBAY
CymaBay Therapeutics
1.6$4.80-1.3%$330.66 millionN/A-5.11Increase in Short Interest
Immunic logo
IMUX
Immunic
1.5$15.95-1.9%$330.45 millionN/A-5.41Analyst Revision
News Coverage
Gap Up
NATR
Nature's Sunshine Products
1.0$16.48-3.2%$323.96 million$362.21 million19.86News Coverage
Gap Down
Arbutus Biopharma logo
ABUS
Arbutus Biopharma
1.4$3.75-1.6%$318.41 million$6.01 million-3.05Upcoming Earnings
Analyst Report
Decrease in Short Interest
Analyst Revision
News Coverage
Gap Down
TFF Pharmaceuticals logo
TFFP
TFF Pharmaceuticals
1.4$14.22-1.6%$316.05 millionN/A-5.39High Trading Volume
Evofem Biosciences logo
EVFM
Evofem Biosciences
1.5$3.87-3.6%$314.55 millionN/A-1.98Upcoming Earnings
News Coverage
NXTC
NextCure
1.6$11.36-1.8%$313.00 million$6.35 million-10.05News Coverage
Gap Down
Theratechnologies logo
THTX
Theratechnologies
1.1$3.21-3.4%$301.23 million$63.22 million-10.35Earnings Announcement
Analyst Downgrade
Increase in Short Interest
News Coverage
Gap Up
BELLUS Health logo
BLU
BELLUS Health
1.8$3.82-2.6%$299.25 million$30,000.00-6.47Earnings Announcement
Decrease in Short Interest
Alpine Immune Sciences logo
ALPN
Alpine Immune Sciences
1.8$11.72-2.6%$278.97 million$1.74 million-8.14Analyst Downgrade
High Trading Volume
News Coverage
Kamada logo
KMDA
Kamada
1.4$6.14-2.0%$273.35 million$127.19 million12.79
MediciNova logo
MNOV
MediciNova
1.2$5.58-2.5%$271.64 millionN/A0.00Upcoming Earnings
Decrease in Short Interest
News Coverage
Xeris Pharmaceuticals logo
XERS
Xeris Pharmaceuticals
1.6$5.45-0.7%$266.92 million$2.72 million-1.37
Galecto logo
GLTO
Galecto
1.6$10.39-13.4%$262.46 millionN/A0.00High Trading Volume
Decrease in Short Interest
Gap Down
LRMR
Larimar Therapeutics
1.7$17.07-0.8%$262.13 millionN/A-3.20Upcoming Earnings
Galera Therapeutics logo
GRTX
Galera Therapeutics
1.6$10.49-0.1%$261.74 millionN/A-3.01
Oramed Pharmaceuticals logo
ORMP
Oramed Pharmaceuticals
1.3$8.91-0.4%$261.69 million$2.71 million-15.36Increase in Short Interest
Gap Down
Tyme Technologies logo
TYME
Tyme Technologies
1.3$2.00-5.0%$260.85 millionN/A-9.09Increase in Short Interest
Gap Down
Hookipa Pharma logo
HOOK
Hookipa Pharma
1.2$11.84-1.6%$258.72 million$11.94 million-7.22News Coverage
Onconova Therapeutics logo
ONTX
Onconova Therapeutics
1.3$1.25-8.8%$258.37 million$2.18 million-0.84Increase in Short Interest
Gap Down
Tricida logo
TCDA
Tricida
1.9$5.11-44.0%$256.45 millionN/A-0.95Earnings Announcement
High Trading Volume
Unusual Options Activity
News Coverage
Gap Down
NuCana logo
NCNA
NuCana
1.5$5.28-3.0%$256.05 millionN/A-5.23Decrease in Short Interest
News Coverage
Oncternal Therapeutics logo
ONCT
Oncternal Therapeutics
1.4$6.53-3.7%$254.76 million$2.42 million-5.73Analyst Report
Decrease in Short Interest
News Coverage
Gap Down
Kezar Life Sciences logo
KZR
Kezar Life Sciences
1.3$5.48-1.3%$253.55 millionN/A-4.38Increase in Short Interest
News Coverage
Gap Down
This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.